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Abstract
Background: In acute situations such as acute myocardial infarction (AMI) with indication for coronary artery bypass
grafting (CABG), total arterial revascularization (TAR) is often rejected in favour of saphenous vein (SV) grafting, which is
assumed to allow for quicker vessel harvesting, a simpler anastomosis technique, and thus quicker revascularization
and fewer bleeding complications. The aim of this study was to evaluate whether reluctance to apply TAR in AMI is still
justified from a technical point of view in the current era and whether superiority of TAR results is also evident in
emergency patients with AMI undergoing CABG.
Methods: In this retrospective analysis of 434 consecutive patients undergoing CABG for AMI with either TAR or with a
combination of one internal mammary artery and SV grafts between 2008 and 2014, procedural data, short-term and
mid-term outcome were compared. Propensity score matching of the groups was performed.
Results: After propensity score matching, 250 patients were included in the analysis (TAR group: n= 98; SV group n= 152).
The procedural time (TAR group: 211 min vs. SV group: 200 min, p= 0.46) did not differ between the groups. Erythrocyte
transfusion rates were higher in the SV group (76% vs. 57%; p < 0.001). Rates of re-exploration for bleeding did not differ.
Thirty-day mortality rates were comparable (TAR group: 3.4% vs. SV group: 4.5%, p = 0.68). Kaplan-Meier analysis until
7 years postoperatively revealed a tendency for improved survival after TAR (75% vs. 62%; log-rank p = 0.12).
Conclusion: TAR neither impairs rapid revascularization nor reduces its safety in patients with AMI. It may result in
improved long-term outcome and should be preferred in the clinical setting of AMI.
Keywords: Acute myocardial infarction, Coronary artery disease, Coronary artery bypass grafting surgery, Revascularization,
Total arterial revascularization
Background
The use of arterial grafts for coronary artery bypass
grafting surgery (CABG), particularly bilateral internal
mammary arteries (BIMA), is recommended due to the su-
perior patency of these grafts compared with saphenous
vein grafts (SV grafts) [1]. In real-world practice, however,
the utilization of total arterial revascularization (TAR) lags
behind these recommendations [2–5]. Reasons for
reluctance to conduct total arterial CABG even in stable
patients include the increased technical demand, the
increased operation time, and fear of bleeding complica-
tions and impaired wound healing [6–8]. In patients
undergoing CABG for acute myocardial infarction (AMI),
large-scale data on TAR rates is limited, and rates ranging
from 2 to 58% have been described [9, 10]. In the unstable
situation of AMI, the above-mentioned arguments against
total arterial CABG might play an even more important
role for decision-making, as patients with AMI undergoing
urgent or emergent surgery would be expected to benefit
from short operation times and rapid revascularization
afforded by use of venous grafting. Furthermore, AMI pa-
tients are frequently administered dual antiplatelet therapy
(DAPT) preoperatively, resulting in increased risk of bleed-
ing complications [11–13].
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It is currently unclear whether these concerns about
the use of TAR in patients with AMI are valid in the
current era of surgical myocardial revascularization. Fur-
thermore, the possible effect of total arterial CABG on
long-term outcome in AMI patients has never been
explicitly investigated.
Methods
Study population
We conducted a retrospective, single-centre study com-
paring patients undergoing total arterial CABG (total
arterial revascularization group [TAR group]) or CABG
with a combination of one internal mammary artery
(IMA) and saphenous vein grafts (saphenous vein graft
group [SV group]). Adult patients with a diagnosis of
AMI (non-ST-segment elevation myocardial infarction
[NSTEMI] or ST-segment-elevation myocardial infarc-
tion [STEMI]) within a period of 5 days or less before
CABG without concomitant procedures (e.g. valve
surgery) between 01/2008 and 12/2014 were included
in the analysis. Patients with low cardiac output
syndrome (LCOS) or cardiogenic shock at the time of
surgery were excluded. The local ethics committee
approved the study.
Data collection, follow-up, definitions
Patients were identified according to the inclusion
criteria from institutional patient records, and their
baseline characteristics and perioperative data from the
patient records and from data transferred to the nation-
wide quality assurance system (BQS Institute for Quality
and Patient Safety, Hamburg, Germany) were analysed.
Long-term follow-up was conducted via telephone inter-
views with the patients or their family physicians.
AMI was defined according to the Third Universal
Definition of AMI [14]. The time of AMI was defined as
the time of symptom onset. ‘Complete revascularization’
was defined using the concept of anatomical complete
numeric revascularization’ (bypassing of all vessels
≥1 mm with hemodynamically relevant stenosis, as
assessed by coronary angiography) [15]. We quantified
the surgeon’s experience according to the years in
practice since board certification as cardiac surgeon.
Endpoints
We compared intraoperative parameters (duration of
surgery, completeness of revascularization), perioperative
need for invasive ventilation, perioperative transfusion
requirements and bleeding complications, acute kidney
injury as defined by KDIGO (Kidney disease: improving
global outcomes) [16], sternal wound impairment requir-
ing surgical therapy, postoperative duration of intensive
care unit stay and hospitalization, as well as short- and
mid-term survival between the groups.
Management strategy
Patients who underwent cardiac catheterization for AMI
are referred to our unit immediately after completion of
the angiographic diagnosis and the heart team-based
decision for CABG. The timing of surgery is deter-
mined by the surgeon on duty. CABG with the goal of
complete revascularization is routinely performed
on-pump with cardioplegic arrest using cold-blood
cardioplegia (Buckberg) [17]. Acetylsalicylic acid is
started 6 h postoperatively and continued lifelong at
100 mg/day. P2Y12 inhibitors are started on the first
postoperative day and are continued for 12 months.
Statistics
An inferential statistical analysis was performed using
SPSS Version 24 (IBM, Armonk, NY, USA), GraphPad
Prism version 6 software (GraphPad Software, Inc., La
Jolla, CA, USA), and R version 3.1.2. Patient characteris-
tics and outcomes were compared using Fisher’s exact
test, Student’s t-test, or Wilcoxon-Mann-Whitney test,
as appropriate. Continuous variables are presented as
mean ± standard deviation (SD) unless stated otherwise.
In order to correct for potential confounding baseline
parameters between the TAR group and the SV group,
we carried out propensity score matching of the groups.
Covariates included in the matching were age, gender,
body-mass index, extent of coronary artery disease,
preoperative left ventricular ejection fraction, diabetes
mellitus (absence thereof, presence without insulin treat-
ment, presence with insulin treatment), and EuroSCORE
II. Nearest-neighbour matching in a 1:2 (TAR group vs.
SV group) fashion was then performed. The maximum
caliper between matched participants was set at 0.2.
Long-term survival functions were determined using
Kaplan-Meier estimation and compared using the
log-rank test.
Results
Baseline data
A total of 434 patients were identified according to the
inclusion criteria. Of these, 293 underwent CABG using a
combination of one internal mammary artery and saphe-
nous vein grafts, 3 underwent CABG with only vein grafts,
and 138 underwent CABG using TAR. Baseline character-
istics between the TAR group and the SV group differed
significantly, with the TAR group having a lower propor-
tion of female patients (17% vs. 29%; p = 0.011), a lower
mean age (59 years vs. 71 years; p < 0.01), a lower rate of
chronic kidney disease and a lower rate of patients with
severely reduced left-ventricular ejection fraction (Table 1).
Consecutively, the operative risk estimation using Euro-
SCORE II was lower in the TAR group than in the SV
group (3.4% vs. 7.2%; p < 0.01) (Table 1). After propensity
score matching, 250 patients (TAR group: n = 98, SV
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group: n = 152) remained in the analysis. The differences
in baseline characteristics were eliminated (Table 1). All
results described in the following refer to the matched
groups. All patients received antiplatelet therapy before
surgery, and 33% in the TAR group and 34% in the SV
group (p = 0.71) were on DAPT at the time of surgery.
Otherwise, tirofiban was used for bridging until 4 h before
surgery (TAR group: 65% vs. SV group: 60%; p = 0.41).
Table 1 Baseline characteristics of the unmatched (left) and matched (right) groups
Unmatched study population Matched study population
Parameter SV group *
n = 296
TAR group *
n = 138
p-value SV group *
n = 152
TAR group *
n = 98
p-value
Female gender 85 (29) 24 (17) 0.011 33 (22) 21 (21) 0.96
Body mass index (kg/m2) 28 ± 4.7 28 ± 4.8 0.31 28 ± 5.0 28 ± 4.9 0.99
Age, years 71 ± 9.2 59 ± 10 < 0.01 66 ± 9.6 63 ± 9.8 0.08
NSTEMI 202 (68) 95 (69) 0.90 105 (69) 70 (71) 0.69
STEMI 94 (32) 43 (31) 47 (31) 28 (29)
Coronary artery disease
1 vessel 11 (3.7) 1 (0.7) < 0.01 9 (5.9) 1 (1.0) 0.12
2 vessel 42 (14) 25 (18) 21 (14) 18 (18)
3 vessel 243 (82) 112 (82) 122 (80) 79 (81)
Diabetes mellitus
Without insulin 81 (27) 26 (19) 0.054 42 (27) 20 (20) 0.19
With insulin 50 (17) 15 (11) 29 (19) 11 (11)
Chronic kidney disease
Stage I (GFR > 89 ml/min) 3 (1.0)
120 (41)
0
31 (22.5)
0.034 2 (1.3)
57 (38)
0
29 (30)
0.13
Stage II (GFR 60-89 ml/min) 75 (25) 10 (7.2) 21 (14) 9 (9.2)
Stage III (GFR 30-59 ml/min) 8 (2.7)
11 (3.7)
1 (0.7)
1 (0.7)
2 (1.3) 1 (1.0)
1 (1.0)
Stage IV (GFR 15-29 ml/min) 11 (3.7) 0 6 (3.9) 0
Stage V (GFR < 15 ml/min) 0.046 0.092
Chronic dialysis
Arterial hypertension 281 (95) 129 (95) 0.35 145 (95) 90 (92) 0.25
Hypercholesterinemia 195 (66) 92 (67) 0.87 101 (66) 67 (68) 0.75
Cerebral arterial occlusive disease 42 (14) 10 (14) 0.24 21 (14) 11 (11) 0.55
Peripheral arterial occlusive disease
Fontaine I 6 (2.0) 1 (0.7) 0.078 5 (3.2) 1 (1.0) 0.46
Fontaine II 31 (10) 11 (8.0) 17 (11) 10 (10)
Fontaine III 5 (1.7) 1 (0.7) 1 (0.7) 1 (1.0)
Fontaine IV 7 (2.4) 1 (0.7) 2 (1.3) 1 (1.0)
Chronic obstructive pulmonary disease 32 (11) 11 (8.0) 0.36 16 (11) 8 (8.2) 0.54
PCI before CABG 32 (11) 20 (14) 0.72 12 (7.9) 12 (12) 0.36
Preoperative LVEF
<20% 21 (7.4) 5 (3.7) 0.047 10 (6.9) 4 (4.2) 0.18
20–30% 27 (9.5) 4 (3.0) 8 (5.6) 3 (3.2)
31–50% 99 (35) 45 (33) 57 (40) 29 (31)
>50% 137 (48) 81 (60) 69 (48) 59 (62)
EuroSCORE II 7.2 ± 8.1 3.4 ± 4.6 < 0.01 5.3 ± 6.1 4.8 ± 5.3 0.14
Abbreviations: CABG coronary artery bypass grafting, GFR glomerular filtration rate, LVEF left-ventricular ejection fraction, NSTEMI non-ST-segment elevation myocardial
infarction, PCI percutaneous coronary intervention, SV saphenous vein grafts, STEMI ST-segment-elevation myocardial infarction, TAR total arterial revascularization
aContinuous variables: mean ± SD; categorical variables: n (%)
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Intraoperative data
The procedures were conducted at a median of 72 h after
symptom onset by eight surgeons with a mean experience
of 6.5 ± 4.8 years since board certification. Surgeon experi-
ence differed significantly between the groups (TAR
group: 7.2 ± 4.8 years vs. SV group: 6.0 ± 4.6 years; p =
0.042). In 86% of TAR procedures, BIMA grafting was ap-
plied, and 14% of patients received a combination of IMA
and radial artery grafts. The total procedural times (TAR
group: 211 ± 54 min vs. SV group: 200 ± 52 min; p = 0.46)
did not differ significantly between the groups. The time
on cardiopulmonary bypass (CPB) was significantly
shorter in the TAR group (84 ± 36 min vs. 96 ± 43 min;
p = 0.048) and the duration of cardioplegic arrest was
similar in the two groups (TAR group: 57 ± 20 min vs. SV
group: 58 ± 21 min; p = 0.79); however, the distribution of
these phases was different, with a longer time to CPB in
the TAR group (89 ± 20 min. vs. 45 ± 31 min.; p = 0.04)
(Fig. 1). This discrepancy can be explained by procedural
differences, as the harvesting of both IMA is performed
sequentially, whereas the preparation of one IMA and vein
grafts is usually carried out simultaneously. Interestingly,
the time from the end of CPB to skin closure was signifi-
cantly reduced in the TAR group (36 ± 10 min vs. 59 ±
15 min, p = 0.042). The number of coronary anastomoses
did not differ between the groups, and complete revascu-
larization was achieved in 99% (SV group) and 97% (TAR
group; p = 0.69), respectively (Table 2).
The surgeon’s experience had a significant inverse cor-
relation with the total duration of the procedure (2.9 min
per year of experience), cardiopulmonary bypass time
(2.3 min per year of experience), and cardioplegic arrest
time (1.5 min per year of experience). There were no
significant differences in this relationship between TAR
and SV groups (Fig. 2).
Perioperative outcomes
Fifty-seven percent of TAR group patients received
erythrocyte transfusion compared with 76% of SV group
patients (p = 0.001). Platelet transfusion occurred in 36%
(TAR group) and 37% (SV group; p = 0.86), respectively.
Fresh frozen plasma was transfused in 22% of TAR group
patients and 30% of SV group patients (p = 0.21). In those
patients who received transfusions, the median amount of
transfused erythrocyte units was higher in the SV group
compared with the TAR group (2 vs. 1 unit; p = 0.041).
The amounts of platelet and fresh frozen plasma transfu-
sions were comparable in both groups (Table 3). The rate
of re-explorations due to bleeding was slightly lower in
the TAR group than in the SV group (3.1% vs. 5.9%; p =
0.30) but this was not statistically significant. Interestingly,
surgical revisions for sternal wound healing impairment
were not significantly increased in the TAR group (4.0%)
compared with in the SV group (2.6%; p = 0.52). Serum
levels of troponin I and creatine kinase-isoform MB (CK-
MB) increased postoperatively, which was followed by a
decline until postoperative day 4. The biomarker levels of
the TAR group were slightly lower than those of the SV
group, but this difference was not statistically significant
(Fig. 3). Postoperative intermittent atrial fibrillation
occurred less frequently in the TAR group than on the SV
group (10% vs. 19%, p = 0.059). Acute kidney injury
occurred similarly in both groups. Duration of invasive
ventilation and rates of tracheostomies for long-term ven-
tilation were comparable in both groups. Consecutively,
the median durations of postoperative intensive care unit
Fig. 1 Time course of surgical procedures with either total arterial revascularization or combination of one internal mammary artery and saphenous
vein grafts. Abbreviations: CPB: cardiopulmonary bypass; SV: saphenous vein grafts; TAR: total arterial revascularization
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Table 2 Preoperative and intraoperative data
Parameter SV group *
n = 152
TAR group *
n = 98
p-value
Antiplatelet therapy
ASA 137 (93) 86 (91) 0.44
Ticagrelor 9 (6.1) 10 (11) 0.20
Prasugrel 3 (2.0) 3 (3.2) 0.57
Clopidogrel 44 (30) 20 (22) 0.16
DAPT 51 (34) 32 (33) 0.71
Tirofiban 90 (60) 61 (65) 0.41
Vitamin K antagonists 6 (4.1) 1 (1.0) 0.082
Time interval symptom onset to operation (h)** 72 ± 5.1 72 ± 5.3 0.85
Grafts
LIMA 147 (97) 98 (100) < 0.001
RIMA 2 (1.3) 84 (86)
Radial artery 0 18 (18)
Saphenous vein 152 (100) 0
Coronary anastomoses
Total 3.8 ± 1.1 3.6 ± 1.0 0.11
Arterial grafts 1.5 ± 0.6 3.6 ± 1.0 < 0.001
Venous grafts 2.3 ± 1.0 0 < 0.001
Target vessels
LAD 151 (99) 98 (100) 0.42
RCX 132 (89) 87 (89) 0.59
RCA 116 (76) 80 (82) 0.32
Complete revascularization [n; %] 149 (99) 95 (97) 0.69
Abbreviations: CABG coronary artery bypass grafting, DAPT dual antiplatelet therapy, LAD left anterior descending artery, LVEF left ventricular ejection
fraction, NSTEMI non-ST-segment elevation myocardial infarction, PCI percutaneous coronary intervention, RCA right coronary artery, RCX Ramus
circumflexus, SV saphenous vein grafts, STEMI ST-segment-elevation myocardial infarction, TAR total arterial revascularization
aContinuous variables: mean ± SD; categorical variables: n (%)
bMedian ± SD
Fig. 2 Correlation between surgeon experience and duration of the operation, cardiopulmonary bypass time, and cardioplegic arrest time. Left:
Patients who underwent total arterial revascularization; Right: Patients who underwent revascularization with a combination of one internal
mammary artery and saphenous vein grafts. Abbreviations: SV: saphenous vein grafts; TAR: total arterial revascularization
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stay and postoperative hospitalization were similar in both
groups. Other postoperative data were comparable
between the groups (Table 3).
Mortality and long-term follow up
Mortality at 30 days postoperatively was 4.5% in the SV
group and 3.4% in the TAR group (p = 0.68).. Further
follow-up was complete for 92% of patients with a median
follow-up time of 3.7 ± 2.5 years. Kaplan-Meier estimation
of survival showed a tendency for improved survival in the
TAR group (log-rank p = 0.12) with survival curves begin-
ning to diverge from 4 years postoperatively onwards. The
overall survival probability at 7 years postoperatively was
75% in the TAR group and 62% in the SV group, respect-
ively (Fig. 4). Symptom-driven repeat coronary angiography
was reported by 17% of patients in the TAR group com-
pared with 21% of patients in the SVG group (p = 0.45).
Redo-CABG was performed in 2 patients (1.3%) in the SV
group and 1 patient (1.0%) in the TAR group (p = 0.64).
Discussion
The main finding of this analysis is that CABG using TAR
is feasible in patients with AMI as it provides revasculari-
zation quality and patient safety like that of CABG using a
combination of IMA and SV without increasing the time
required for revascularization. Perioperative outcomes did
not differ significantly between the groups. Bleeding com-
plications and transfusion requirements were not higher
after TAR than after revascularization using IMA/SV; in
contrast, the proportion of patients who did not receive
any red blood cell transfusion was higher in the TAR
group. Postoperative atrial fibrillation was less frequent in
the TAR group, possibly due to reduced red blood cell
transfusion as demonstrated by previous studies [18, 19].
Table 3 Perioperative outcomes
Parameter SV group *
n = 152
TAR group *
n = 98
p-value
Transfusions
Erythrocytes
Rate 116 (76) 56 (57) < 0.001
Amount (units)** 2 ± 2.6 1 ± 2.7 0.041
Platelets
Rate 56 (37) 35 (36) 0.86
Amount (units)** 0 ± 1.0 0 ± 0.90 0.33
Fresh frozen plasma
Rate 45 (30) 22 (22) 0.21
Amount (units)** 0 ± 2.0 0 ± 2.0 0.46
Re-thoracotomy for bleeding 9 (5.9) 3 (3.1) 0.30
Sternal wound healing impairment requiring surgical revision 4 (2.6) 4 (4.0) 0.52
Superficial 2 (1.3) 3 (3.0)
Deep 2 (1.3) 1 (1.0)
Duration of invasive ventilation (hours)** 14 ± 58 10 ± 73 0.61
Postoperative tracheostomy 11 (7.2) 5 (5.1) 0.30
New onset atrial fibrillation 29 (19) 10 (10) 0.059
Stroke (>Rankin1) 3 (2.0) 0 0.1
Acute kidney injury
KDIGO I 59 (40) 32 (33) 0.17
KDIGO II 11 (7.5) 4 (4.1)
KDIGO III 6 (3.9) 5 (5.1)
Postoperative dialysis 6 (3.9) 5 (5.1) 0.69
Postoperative length of ICU stay (hours)** 73 ± 81 46 ± 93 0.28
Postoperative length of hospital stay (days) ** 10 ± 4.5 10 ± 3.4 0.58
30-day all-cause mortality 6 (4.5) 3 (3.4) 0.68
Abbreviations: ECLS extracorporeal life support, KDIGO Kidney disease: improving global outcomes, SV saphenous vein grafts, TAR total arterial revascularization
aContinuous variables: mean ± SD; categorical variables: n (%)
bMedian ± SD
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Nevertheless, if transfusions were necessary, the amount
of transfused erythrocyte units was rather high. This
might be explained by the high rate of patients with DAPT
at the time of surgery [11].
The mean time of surgeon experience was slightly higher
in the TAR group, probably reflecting that more experi-
enced surgeons tend to perform this more challenging
technique in urgent or emergent clinical settings. More-
over, the increased surgeon experience in the TAR group
might result in better surgical results, although recent data
did not confirm this assumption for CABG procedures
[20–22]. Surprisingly, analysis of procedural duration
revealed that the total duration of the surgical procedures
involving total arterial CABG and CABG using vein grafts
were similar. Our data show that the surgeon’s experience
has a significant influence on the duration of the proced-
ure but that the amount is of questionable relevance. The
longer phase of graft preparation in the TAR group was
balanced by a shorter post-CPB phase in the TAR group.
The reduction in reperfusion time and post-CPB time
might be partly explained by the greater experience of the
surgeons involved, leading to more efficient management
at the end of the operation; however, the shorter time
could additionally be explained by more rapid bypass graft
function of arterial grafts compared with vein grafts, pos-
sibly resulting in quicker hemodynamic stabilization. Data
on flow properties of arterial bypass grafts compared those
of with vein grafts in the immediate intraoperative phase
are limited: Spence et al. showed in a canine model that
mammary artery graft flow is not impaired by competitive
flow from the native vessel [23]. As competitive flow from
either the native vessel or collaterals is frequently observed
in the early and late postoperative phase, resilience of the
grafts may influence their immediate and long-term func-
tion [24]. Concerning the immediate function, Weber et al.
described improved intraoperative pulsatility indices and a
tendency for reduced perioperative myocardial infarctions
when using IMA grafts compared with vein grafts [25].
We cannot substantiate our assumption of improved im-
mediate bypass graft function, as flow measurements were
not routinely carried out at our institution. Furthermore,
although the postoperative increase in serum levels of car-
diac biomarkers was somewhat less in the TAR group than
in the SV group (possibly reflecting reduced cardiac injury
resulting from improved bypass function), this difference
was not statistically significant.
Fig. 3 Cardiac injury parameters measured until postoperative day 4. Abbrevisations: CK-MB: Creatine kinase – isoform MB; POD: postoperative day; SV:
saphenous vein grafts; TAR: total arterial revascularization
Fig. 4 Kaplan-Meier analysis comparing survival of patients who
underwent total arterial revascularization or revascularization with a
combination of one internal mammary artery and saphenous vein
grafts. Abbreviations: TAR: total arterial revascularization; SV: saphenous
vein grafts
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We were also surprised to observe that the most tech-
nically challenging phase of the procedure, the comple-
tion of the coronary anastomoses during cardioplegic
arrest, required the same amount of time in the two
groups, which is not in keeping with the reluctance to
perform TAR due to more difficult and prolonged com-
pletion of coronary anastomoses. In fact, the present
data should encourage surgeons to commit themselves
early to TAR concepts, as these are feasible without loss
of time in experienced hands.
Data from the postoperative follow-up period of up to
7 years did not show significant differences in survival be-
tween the groups; however, there was a tendency for im-
proved survival in the TAR group from 4 years onwards.
The rate of reported symptom-driven repeat coronary
catheterizations were non-significantly lower in the TAR
group. Unfortunately, there is no information available
about the results of these coronary catheterizations and
interventions performed. Redo-CABG occurred similarly
in both groups. Previous studies have demonstrated that
differences in graft patency between SV and IMA grafts
become evident only after 4–8 years [26, 27, 28]. A sur-
vival benefit after TAR in the mid- or long-term has been
shown in pooled analyses [29, 30]. Our observation is in
accordance with the recently published work by Taggart et
al. showing no significant survival benefit after bilateral
IMA versus single IMA grafting after 5 years [31]. A
longer-term follow-up of the patients will be required to
confirm these observations.
Several limitations of this study should be mentioned.
First, patients with LCOS prior to surgery were excluded
from this analysis, as CABG in these patients frequently
does not follow the standardized sequence of operative
steps. These patients are often placed on CPB prior to
graft harvesting, and BIMA preparation is all but ruled
out in these emergency situations, and hence we did not
consider these exceptional, very individual situations to
be suitable for a generalizable analysis. Therefore, the
results of this study cannot be applied to patients who
present with LCOS before CABG. Second, CPB with car-
dioplegic arrest was used in all procedures. Alternative
approaches include off-pump CABG or on-pump CABG
with beating heart [32–34], which might reduce injury
and inflammation associated with CPB and cardioplegic
arrest. CPB with cardioplegic arrest, however, provides
hemodynamic stability during the procedure with opti-
mized exposure for accurate anastomosing. To date
there are no data available showing superiority of one
strategy over the other.
Although the logistical and technical aspects (proced-
ural times, completeness of revascularization) of our study
are not likely to be biased by the study design, outcome
data of this retrospective, propensity-matched analysis
should be considered with caution. Unknown confounders
might reduce comparability of the groups and bias
outcome data.
Conclusion
TAR should be considered the standard of care in
hemodynamically stable patients with AMI undergoing
CABG, as it is equally safe and rapid compared with the
use of combinations of IMA and vein grafts. Reluctance to
apply TAR in these patients due to fear of protracted
revascularization and bleeding complications is no longer
justified. Long-term outcome may be improved after TAR,
but these observations remain to be confirmed in a
longer-term study.
Abbreviations
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